Introduction: Anakinra is an anti-IL-1RA targeting IL-1β with a central role in the occurrence of auto-inflammatory diseases. Its use is not without risk.
Case report: We report a case of late onset auto-inflammatory syndrome treated with anti-IL-1RA whose progression was marked by deep isolated thrombocytopenia, rapidly regressive after discontinuation of anakinra.
Conclusion: Immuno-allergic thrombocytopenia to anakinra is a rare, but serious adverse event.
Keywords: Anakinra; Anti-IL-1RA; Auto-inflammatory syndrome; Drug-induced immune thrombocytopenia; IL-1; Syndrome auto-inflammatoire; Thrombocytopénie immunitaire d’origine médicamenteuse.
Copyright © 2019 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.